Biotoxtech KRX:086040KOSDAQ
바이오톡스텍 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Biotoxtech reported revenue of ₩16.1bn, up 35.0% year on year, and operating profit of ₩579m. Biotoxtech (바이오톡스텍) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 1 article.
Filing signals Turnaround Revenue +30% Insider buying Major holder adding Screener
Biotoxtech at a glance from DART filings
- Results trend
- Operating profit in 1 of the last 4 quarters; Q3 2026 operating profit of ₩579m swung to a profit from a loss in the previous quarter.
- Ownership changes
- 18 5%-holder and insider ownership reports in the past 120 days (17 increases, 1 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Biotoxtech today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Biotoxtech stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Biotoxtech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩16.1bn | +35.0% | ₩579m margin 3.6% | −₩1.3bn |
| Q2 2026 | ₩14.5bn | +50.3% | −₩182m margin −1.3% | −₩6.9bn |
| Q1 2026 | ₩11.9bn | +5.5% | −₩1.8bn margin −15.4% | −₩2.7bn |
| Q4 2025 derived | ₩14.2bn | +24.7% | −₩98m margin −0.7% | −₩2.0bn |
| Q3 2025 | ₩11.9bn | +7.0% | −₩1.4bn margin −11.5% | ₩4.5bn |
| Q2 2025 | ₩9.6bn | -1.9% | −₩1.9bn margin −20.0% | −₩2.0bn |
| Q1 2025 | ₩11.2bn | +25.1% | −₩1.4bn margin −12.6% | −₩2.1bn |
| Q4 2024 derived | ₩11.4bn | +34.0% | −₩1.4bn margin −12.3% | −₩4.0bn |
Biotoxtech ranks #1228 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Biotoxtech top stories 2 weeks, by number of outlets
- 1